EU proposes changes to IP rules, legalizes generic drug production

Date: 2018-05-30   Author: Saipriya Iyer  Category: #news

EU proposes changes to IP rules, legalizes generic drug production

The European Commission has decided to make amendments in its intellectual property legislations in order to encourage pharmaceutical firms to manufacture generic medicines. The drug production would be slated for the nations where they are not covered under extended copyright protection.

The EU had introduced supplementary protection certificates that help in extending the duration of specific rights linked with the patents post their expiry period. The EC states that while these guidelines were initiated to support the research funding in Europe, many of the drug manufacturing firms are now looking towards production of generic drugs for non-European nations.

Sources cite that with the changes in the EU’s intellectual property laws, biosimilar firms in Europe will now be able to produce generic medicines in Europe and then export them to those regions where no laws related to copyright protection exist. Elzbieta Bienkowska, an EU Industry Commissioner, has announced that the move is aimed at generating a business of nearly ninety-five billion euros across the globe. She further added that EC took inspiration from Canada, where the strategy worked successfully and helped in the expansion of the pharma sector in the country in addition to offering jobs for the locals.

According to the EC, the proposal can generate net sales of nearly USD 1.2 billion each year after it receives approval from the European parliament as well twenty-eight-member countries of the EU. However, some of the original drug manufacturers have claimed that the decision can weaken the IP protection and can adversely impact the funding of the research activities in Europe.

The European Federation of Pharmaceutical Industries has raised concerns over the decision taken by the EC and has commented that the generic drug manufacturing waiver will pose a risk for the patient access to new therapies. But, the Medicines for Europe, representing generic drug manufacturers, has defended the decision of EU, emphasizing that it will help in the reduction of the medicine costs, thereby benefitting the Europe healthcare market.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Intelligent Process Automation(IPA) Market Covid-19 Impact In-Depth Industry Analysis 2026

Author: Ashwin Naphade

The research report on Intelligent Process Automation(IPA) market offers critical information such as the development trends, restraints, CAGR, revenue prospects, product type, application scope, competitive scenario, and COVID-19 impact.

<...


Passive Optical LAN (POL) market players to make profitable investments during 2021-2026

Author: Ashwin Naphade

Global Passive Optical LAN (POL) Market Report provides complete industry analysis, market outlook, size, growth, opportunities and forecast 2026. This report will assist in analyzing the current and future business trends, sales and revenue forec...


Research on Intelligent Machine Control System Market 2021: By Growing Rate, Type, Applications, Geographical Regions, and Forecast to 2026

Author: Ashwin Naphade

Intelligent Machine Control System market report is a comprehensive analysis of the growth dynamics and revenue inflows in this industry sphere over 2021-2026, inclusive of Covid-19 impact.

The latest research report on Intelligent Machi...